At-Home Testing. 15 Minute Results — eMed Brings the Test to You.

Through an exclusive agreement with Abbott, the eMed digital health platform provides greater access to BinaxNOW™, the first virtually-guided, at-home COVID-19 test.

See FDA Emergency Use Authorization

See procedure card

Buy a KitStart testing

How Our Testing Process Works


1. Answer a few questions

Complete our CDC Questionnaire to tell us about your symptoms and exposure.

2. Get a Prescribed Order

An eMed Healthcare Partner will determine if the test is right for you and issue a prescribed order.

3. Delivery or Pick-up

The test is shipped within 24 hours, or pick it up locally.

4. Test at home

Have a virtual visit guided by an eMed Certified Guide.

5. Get results in 15 minutes

Receive follow-up healthcare instructions and a digital pass, if your COVID-19 test is negative.

What’s in the Box

The shortest route to fast results

Inside, you’ll find all you need to conduct a rapid COVID-19 test, authorized for use on a virtual visit with an eMed Certified Guide.

BinaxNOW™ COVID-19 Ag Card

Newly Designed Single-Use Extraction Reagent Bottle

Nasal Swab

The eMed Advantage


We partner with leading manufacturers of government-authorized or approved tests.

At-Home Testing

Our digital point-of-care solution guides you through the test with live video guidance, ensuring proper test procedure and validated results.

Rapid Results

Results are available within minutes of taking the test.

Digital Pass

Users who test negative receive a digital pass, enabling them to return to activities, while still following appropriate safety protocols.

The BinaxNOW™ COVID-19 Ag Card Home Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.